FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566318589> ?p ?o ?g. }

• W2566318589 endingPage "10224" @default.
• W2566318589 startingPage "10213" @default.
• W2566318589 abstract "Multiple Myeloma (MM) is a plasma cell tumor localized to the bone marrow (BM). Despite the fact that current treatment strategies have improved patients' median survival time, MM remains incurable. Epigenetic aberrations are emerging as important players in tumorigenesis making them attractive targets for therapy in cancer including MM. Recently, we suggested the polycomb repressive complex 2 (PRC2) as a common denominator of gene silencing in MM and presented the PRC2 enzymatic subunit enhancer of zeste homolog 2 (EZH2) as a potential therapeutic target in MM. Here we further dissect the anti-myeloma mechanisms mediated by EZH2 inhibition and show that pharmacological inhibition of EZH2 reduces the expression of MM-associated oncogenes; IRF-4, XBP-1, PRDM1/BLIMP-1 and c-MYC. We show that EZH2 inhibition reactivates the expression of microRNAs with tumor suppressor functions predicted to target MM-associated oncogenes; primarily miR-125a-3p and miR-320c. ChIP analysis reveals that miR-125a-3p and miR-320c are targets of EZH2 and H3K27me3 in MM cell lines and primary cells. Our results further highlight that polycomb-mediated silencing in MM includes microRNAs with tumor suppressor activity. This novel role strengthens the oncogenic features of EZH2 and its potential as a therapeutic target in MM." @default.
• W2566318589 created "2017-01-06" @default.
• W2566318589 creator A5002202838 @default.
• W2566318589 creator A5016851019 @default.
• W2566318589 creator A5027815979 @default.
• W2566318589 creator A5035411478 @default.
• W2566318589 creator A5043874461 @default.
• W2566318589 creator A5044696860 @default.
• W2566318589 creator A5049230560 @default.
• W2566318589 creator A5049924304 @default.
• W2566318589 creator A5052542248 @default.
• W2566318589 creator A5067957722 @default.
• W2566318589 creator A5069509150 @default.
• W2566318589 creator A5074053599 @default.
• W2566318589 date "2016-12-30" @default.
• W2566318589 modified "2023-10-12" @default.
• W2566318589 title "EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions" @default.
• W2566318589 cites W144423133 @default.
• W2566318589 cites W1565226021 @default.
• W2566318589 cites W1677557982 @default.
• W2566318589 cites W1876306805 @default.
• W2566318589 cites W1971981721 @default.
• W2566318589 cites W1981403111 @default.
• W2566318589 cites W1989069691 @default.
• W2566318589 cites W1989259853 @default.
• W2566318589 cites W1991899579 @default.
• W2566318589 cites W1993469143 @default.
• W2566318589 cites W1995652309 @default.
• W2566318589 cites W2005100560 @default.
• W2566318589 cites W2012182672 @default.
• W2566318589 cites W2015132841 @default.
• W2566318589 cites W2018651010 @default.
• W2566318589 cites W2023234211 @default.
• W2566318589 cites W2024873523 @default.
• W2566318589 cites W2024985626 @default.
• W2566318589 cites W2025998934 @default.
• W2566318589 cites W2031634495 @default.
• W2566318589 cites W2031692900 @default.
• W2566318589 cites W2032058375 @default.
• W2566318589 cites W2042748226 @default.
• W2566318589 cites W2044832480 @default.
• W2566318589 cites W2046517086 @default.
• W2566318589 cites W2047941151 @default.
• W2566318589 cites W2049702532 @default.
• W2566318589 cites W2054301876 @default.
• W2566318589 cites W2054864726 @default.
• W2566318589 cites W2055662838 @default.
• W2566318589 cites W2056117553 @default.
• W2566318589 cites W2058555823 @default.
• W2566318589 cites W2059368312 @default.
• W2566318589 cites W2059581635 @default.
• W2566318589 cites W2060608189 @default.
• W2566318589 cites W2063032852 @default.
• W2566318589 cites W2073423022 @default.
• W2566318589 cites W2079784129 @default.
• W2566318589 cites W2088091102 @default.
• W2566318589 cites W2094636384 @default.
• W2566318589 cites W2095854115 @default.
• W2566318589 cites W2096497783 @default.
• W2566318589 cites W2103289668 @default.
• W2566318589 cites W2106951570 @default.
• W2566318589 cites W2109578585 @default.
• W2566318589 cites W2111471857 @default.
• W2566318589 cites W2113239055 @default.
• W2566318589 cites W2115397405 @default.
• W2566318589 cites W2117247812 @default.
• W2566318589 cites W2123419812 @default.
• W2566318589 cites W2127419185 @default.
• W2566318589 cites W2130907138 @default.
• W2566318589 cites W2139019465 @default.
• W2566318589 cites W2148941906 @default.
• W2566318589 cites W2153252925 @default.
• W2566318589 cites W2154811915 @default.
• W2566318589 cites W2158414356 @default.
• W2566318589 cites W2162080206 @default.
• W2566318589 cites W2164853398 @default.
• W2566318589 cites W2173745138 @default.
• W2566318589 cites W2175277699 @default.
• W2566318589 cites W2261876703 @default.
• W2566318589 cites W2402661058 @default.
• W2566318589 cites W4211135634 @default.
• W2566318589 cites W4252175385 @default.
• W2566318589 doi "https://doi.org/10.18632/oncotarget.14378" @default.
• W2566318589 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5354653" @default.
• W2566318589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28052011" @default.
• W2566318589 hasPublicationYear "2016" @default.
• W2566318589 type Work @default.
• W2566318589 sameAs 2566318589 @default.
• W2566318589 citedByCount "46" @default.
• W2566318589 countsByYear W25663185892017 @default.
• W2566318589 countsByYear W25663185892018 @default.
• W2566318589 countsByYear W25663185892019 @default.
• W2566318589 countsByYear W25663185892020 @default.
• W2566318589 countsByYear W25663185892021 @default.
• W2566318589 countsByYear W25663185892022 @default.
• W2566318589 countsByYear W25663185892023 @default.
• W2566318589 crossrefType "journal-article" @default.
• W2566318589 hasAuthorship W2566318589A5002202838 @default.

• next